Our promising pipeline of
innovative product candidates are
designed to target and help resolve
serious unmet medical needs

Our Pipeline

Pushing the boundaries of breakthrough therapies


Ivonescimab (SMT112)
Summit is initiating development activities for SMT112 and will do so first in NSCLC indications.
Summit plans to start treating patients in clinical studies by the second quarter of 2023.

Summit Research
Focused on innovations leveraging deep leadership expertise in discovery and advancement of novel molecules, including ivonescimab.

*Phase I and II has been completed by our partner Akeso, Phase III clinical studies are planned to be initiated either independently or jointly with our partner Akeso in 2023/24

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.
It is currently being investigated in Phase III clinical studies.